tetano
Editor, Senior Moderator
Respir Res. 2020 Apr 15;21(1):83. doi: 10.1186/s12931-020-01352-w.
Prognostic value of NT-proBNP in patients with severe COVID-19.
Gao L[SUP]1[/SUP], Jiang D[SUP]2[/SUP], Wen XS[SUP]1[/SUP], Cheng XC[SUP]1[/SUP], Sun M[SUP]1[/SUP], He B[SUP]1[/SUP], You LN[SUP]1[/SUP], Lei P[SUP]1[/SUP], Tan XW[SUP]1[/SUP], Qin S[SUP]1[/SUP], Cai GQ[SUP]3,[/SUP][SUP]4[/SUP], Zhang DY[SUP]5[/SUP].
Author information
Abstract
BACKGROUND:
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown.
METHODS:
The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records.
RESULTS:
The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death.
CONCLUSION:
NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19.
TRIAL REGISTRATION:
ClinicalTrials, NCT04292964. Registered 03 March 2020.
KEYWORDS:
COVID-19; NT-proBNT; Outcome; SARS-CoV-2
PMID:32293449PMCID:PMC7156898DOI:10.1186/s12931-020-01352-w
Free PMC Article
Prognostic value of NT-proBNP in patients with severe COVID-19.
Gao L[SUP]1[/SUP], Jiang D[SUP]2[/SUP], Wen XS[SUP]1[/SUP], Cheng XC[SUP]1[/SUP], Sun M[SUP]1[/SUP], He B[SUP]1[/SUP], You LN[SUP]1[/SUP], Lei P[SUP]1[/SUP], Tan XW[SUP]1[/SUP], Qin S[SUP]1[/SUP], Cai GQ[SUP]3,[/SUP][SUP]4[/SUP], Zhang DY[SUP]5[/SUP].
Author information
Abstract
BACKGROUND:
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury is a common condition among the hospitalized patients with COVID-19. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of severe COVID-19 patients was unknown.
METHODS:
The study initially enrolled 102 patients with severe COVID-19 from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. The primary outcome was in-hospital death defined as the case fatality rate. Research information and following-up data were obtained from their medical records.
RESULTS:
The best cut-off value of NT-proBNP for predicting in-hospital death was 88.64 pg/mL with the sensitivity for 100% and the specificity for 66.67%. Patients with high NT-proBNP values (> 88.64 pg/mL) had a significantly increased risk of death during the days of following-up compared with those with low values (≤88.64 pg/mL). After adjustment for potential risk factors, NT-proBNP was independently correlated with in-hospital death.
CONCLUSION:
NT-proBNP might be an independent risk factor for in-hospital death in patients with severe COVID-19.
TRIAL REGISTRATION:
ClinicalTrials, NCT04292964. Registered 03 March 2020.
KEYWORDS:
COVID-19; NT-proBNT; Outcome; SARS-CoV-2
PMID:32293449PMCID:PMC7156898DOI:10.1186/s12931-020-01352-w
Free PMC Article